Press "Enter" to skip to content

New patent for Loxo Oncology drug RETEVMO

1
Copyright © DrugPatentWatch. Originally published at New patent for Loxo Oncology drug RETEVMO

Annual Drug Patent Expirations for RETEVMO
Annual Drug Patent Expirations for RETEVMO

Retevmo is a drug marketed by Loxo Oncology Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

This drug has thirty-four patent family members in twenty-four countries.

The generic ingredient in RETEVMO is selpercatinib. One supplier is listed for this compound. Additional details are available on the selpercatinib profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Loxo Oncology drug RETEVMO

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!